イルベサルタンの中国市場

調査会社China Research and Intelligence社が発行したリサーチレポート(データ管理コード:DATA8102366)
◆英語タイトル:Investigation Report on China's Irbesartan Market, 2018-2022
◆発行会社/調査会社:China Research and Intelligence
◆商品コード:DATA8102366
◆発行日:2018年9月
◆調査対象地域:中国
◆産業分野:製薬
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,200 ⇒換算¥237,600見積依頼/購入/質問フォーム
EnterprisewideUSD3,300 ⇒換算¥356,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
China Research and Intelligence社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[イルベサルタンの中国市場]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

DescriptionSartans are antihypertensive drugs with highly selective, effective and long-lasting multi-organ targeted protection. With a more specific mechanism of action, they prevent dry cough and other side effects that may be caused by angiotensin-converting enzyme inhibitors (ACEIs), and thus have replaced the ACEIs in some clinical uses. As a result, the growth of the ACEI market slows down, which leading to a steady increase in the Sartans market. Another growth driver is the new edition of List of Medicines Covered by National Basic Medical Insurance that included compound preparations.
Irbesartan was developed by Sanofi, first approved by the European Medicines Agency (EMA) on Aug. 27, 1997, and then approved by the U.S. Food and Drug Administration (FDA) on Sept. 30, 1997. The trade name of Sanofi’s Irbesartan is Aprovel. Irbesartan is mainly used to treat primary hypertension and has little effect on heart rate. Irbesartan can also protect kidneys and slow the progression of diabetic nephropathy. It can slow the progression of kidney disease for patients with both type 2 diabetic nephropathy and hypertension.
According to CRI, domestic enterprises developed the generic versions of Aprovel early. The generic drugs were approved to be sold in China in 2000. By Sept. 2018, there are 11 Irbesartan API manufacturers, and 24 manufacturers of Irbesartan tablets, capsules and dispersible tablets in China. The Irbesartan products of Sanofi and its subsidiary Sanofi (Hangzhou) Pharmaceutical Co., Ltd. have an absolute advantage in China, taking up approximately 80% market share by sales value in 2017.
There were about 330 million hypertensive patients in China at the end of 2017. One in every three adults has high blood pressure. Chinese hypertensive patients account for about one-third of the global total. The incidence of hypertension in China rose by 32.1% from 5.1% in 1959 to 37.2% in 2017.
The sales value of Irbesartan was on the rise after it entered China, exceeding CNY 300 million in 2017. It is expected that the market size will continue to grow from 2018 to 2022 with the increasing number of hypertensive patients.

Topics Covered:
- Development environment of China’s Irbesartan market
- Market demand for Irbesartan in China
- Analysis on competition on China’s Irbesartan market
- Analysis on major Irbesartan manufacturers in China
- Driving forces for China’s Irbesartan market from 2018 to 2022
- Prospect of China’s Irbesartan market from 2018 to 2022

*** レポート目次(コンテンツ)***

Table of Contents
1 Relevant Concepts of Irbesartan
1.1 Indications for Irbesartan
1.2 Development History of Irbesartan in China
1.3 Governmental Approval of Irbesartan in China

2 Sales of Irbesartan in China, 2013-2017
2.1 Sales Value
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Irbesartan by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules

3 Analysis on Major Competitors on China’s Irbesartan Market, 2013-2017
3.1 Analysis on Market Share of Major Irbesartan Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.’s Irbesartan in China9
3.3 Sanofi
3.3.1 Enterprise Profile
3.3.2 Sales of Sanofi’s Irbesartan in China
3.4 Jiangsu Hengrui Medicine Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Jiangsu Hengrui Medicine Co., Ltd.’s Irbesartan in China
3.5 Zhuhai Rundu Pharmaceutical Co., Ltd.
3.6 Weifang Zhongshi Pharmaceutical Co., Ltd.

4 Prices of Irbesartan in China, 2017-2018
4.1 Sanofi (Hangzhou) Pharmaceutical Co., Ltd. (Aprovel)
4.2 Sanofi (Aprovel)
4.3 Jiangsu Hengrui Medicine Co., Ltd. (Jijia)
4.4 Zhuhai Rundu Pharmaceutical Co., Ltd. (Yitaiqing)
4.5 Weifang Zhongshi Pharmaceutical Co., Ltd. (Bida)

5 Prospect of China’s Irbesartan Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend

Selected Charts
Chart Sales of Irbesartan in China, 2013-2017
Chart Sales Value of Irbesartan in Parts of China, 2013-2017
Chart Sales Volume of Irbesartan in China, 2013-2017
Chart Sales Volume of Irbesartan in Parts of China, 2013-2017
Chart Sales Value of Irbesartan Tablets in China, 2013-2017
Chart Sales Value of Irbesartan Capsules in China, 2013-2017
Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Irbesartan Manufacturers by Sales Volume in China, 2013-2017
Chart Profile of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.
Chart Sales Value of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.’s Irbesartan, 2013-2017
Chart Profile of Sanofi
Chart Sales Value of Sanofi’s Irbesartan in China, 2013-2017
Chart Sales Value of Jiangsu Hengrui Medicine Co., Ltd.’s Irbesartan, 2013-2017
Chart Prices of Sanofi (Hangzhou) Pharmaceutical Co., Ltd.’s Irbesartan in Parts of China, 2017-2018
Chart Prices of Sanofi’s Irbesartan in Parts of China, 2017-2018
Chart Prices of Jiangsu Hengrui Medicine Co., Ltd.’s Irbesartan in Parts of China, 2017-2018
Chart Forecast on Sales Value of Irbesartan in China, 2018-2012



*** レポートのキーワード ***

イルベサルタン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • バイオチップのアジア市場予測2018-2026
    KEY FINDINGSThe revenue generated by the Asia-Pacific biochip market is expected to progress with an estimated CAGR of 21.13% between the forecast years of 2018-2026. MARKET INSIGHTS Technological advancement in biotechnology, rising number of applications for biochips and the overall scope for biot …
  • Intercept Pharmaceuticals, Inc.:製薬企業の製品開発パイプライン動向2014
    Intercept Pharmaceuticals, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct’s, ‘Intercept Pharmaceuticals, Inc. - Product Pipeline Review - 2014’, provides an overview of the Intercept Pharmaceuticals, Inc.’s pharmaceutical research and development focus. This report provides comp …
  • 誘導型一酸化窒素合成酵素阻害剤のパイプライン・インサイト2018
    SUMMARY DelveInsight’s, “Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitors-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Inducible Nitric Oxide Synthase (iNOS or Type II NOS) Inhibitors. The DelveInsight’s …
  • 保険料データ(~2017):Bermuda
    This report is the result of Timetric’s extensive market research covering the insurance industry in Bermuda. It contains detailed historic and forecast data for gross claims. 'Gross Claims in Bermuda to 2017: Market Snapshot' provides detailed insight into the operating environment of the insurance …
  • スイスの装具市場見通し
    Switzerland Orthotic Devices Market Outlook to 2022 Summary GlobalData’s new report, Switzerland Orthotic Devices Market Outlook to 2022, provides key market data on the Switzerland Orthotic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price …
  • ウクライナのベーカリー及びシリアル食品市場
    Summary This report brings together consumer insight and market data to provide a comprehensive brief of Ukraine's Bakery and Cereals market. This allows for the rapid identification of key growth opportunities across major Bakery and Cereals categories and their packaging. Key Findings - Ukraine's …
  • 世界のマルチメディアフィルター市場2017
    Multi Media Filter Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Ger …
  • 世界のスクリューエアコンプレッサー市場2016
    Notes:Production, means the output of Screw Air Compressor Revenue, means the sales value of Screw Air Compressor This report studies Screw Air Compressor in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, wit …
  • m-ニトロベンゼンスルホン酸の世界市場2019
    The Global M-Nitrobenzenesulfonicacid (CAS 98-47-5) Industry 2019 Market Research Report is a professional and in-depth study on the current state of the M-Nitrobenzenesulfonicacid industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applica …
  • カリウムミョウバンウランの世界及び中国市場 2018年
    The 'Global and Chinese Potassium Alum Uranium Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Potassium Alum Uranium industry with a focus on the Chinese market. The report provides key statistics on the market status of the Potass …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DATA8102366 )"イルベサルタンの中国市場" (英文:Investigation Report on China's Irbesartan Market, 2018-2022)はChina Research and Intelligence社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。